hm15136
Peptideexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 2, 2018 (NCT04032782)
Timeline
Indications
Mechanism of action
- Glucagon receptorAGONIST
GCGR agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04732416 | Phase 2 | Oct 30, 2021 | Hanmi Pharmaceutical |
| NCT04167553 | Phase 1 | Aug 30, 2019 | Hanmi Pharmaceutical |
| NCT04032782 | Phase 1 | Oct 2, 2018 | Hanmi Pharmaceutical |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanmi Pharmaceutical | For profit | 3 | 3 | 2 | 2018 |
1 organizations
Page 1 / 1